[CONSOLIDATION_METHOD_TITLE] [CONSOLIDATION_METHOD]
Related Companies
[]
Related Funds
[]
English
oda_MaterialEventDisclosureGeneralAbstract|
Material Event Disclosure General
oda_UpdateAnnouncementFlag|
Update Notification Flag
Evet (Yes)
oda_CorrectionAnnouncementFlag|
Correction Notification Flag
Hayır (No)
oda_DateOfThePreviousNotificationAboutTheSameSubject|
Date Of The Previous Notification About The Same Subject
27.09.2022
oda_DelayedAnnouncementFlag|
Postponed Notification Flag
Hayır (No)
oda_AnnouncementContentSection|
Announcement Content
oda_ExplanationSection|
Explanations
oda_ExplanationTextBlock|
Briefly, in the statement that we made on September 27, 2022; on the Board of Directors of our business partnership Eczacıbaşı Monrol Nükleer Ürünler San. ve Tic. A.Ş. (Eczacıbaşı Monrol); in line with the goal of expanding its products and services in foreign markets, it was announced that it is decided to establish a limited company, with the title of Monrol GmbH and a share capital of 25,000 Euros in Germany, for the development and production of radiopharmaceutical products.
The incorporation process of Monrol GmbH, of which share capital is wholly owned (100%) by Eczacıbaşı Monrol, has been completed by being registered in the Trade Registry in Germany.

This statement has been translated into English for informational purposes. In case of a discrepancy between the Turkish and the English versions of this disclosure statement, the Turkish version shall prevail.